Media coverage about Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Valeant Pharmaceuticals Intl earned a coverage optimism score of 0.11 on Accern’s scale. Accern also assigned media stories about the specialty pharmaceutical company an impact score of 46.2901278731392 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the news articles that may have effected Accern’s rankings:
- ValuEngine Lowers Valeant Pharmaceuticals Intl (VRX) to Hold (americanbankingnews.com)
- TD Securities Cuts Valeant Pharmaceuticals Intl (VRX) Price Target to $23.00 (americanbankingnews.com)
- Valeant lands rights to potential psoriasis drug ahead of earnings (marketwatch.com)
- Could Valeant Stock Tumble Another 40% From Here? (msn.com)
- Stock’s Technical Analysis: Valeant Pharmaceuticals International Inc (NYSE: VRX) – Alpha Beta Stock (alphabetastock.com)
Valeant Pharmaceuticals Intl (VRX) traded down $1.13 during mid-day trading on Thursday, reaching $15.26. 29,728,571 shares of the company were exchanged, compared to its average volume of 12,720,000. The firm has a market cap of $5,310.00, a PE ratio of 3.91, a PEG ratio of 0.58 and a beta of -0.42. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 4.84. Valeant Pharmaceuticals Intl has a one year low of $8.31 and a one year high of $24.43.
A number of research analysts have commented on VRX shares. Zacks Investment Research downgraded shares of Valeant Pharmaceuticals Intl from a “hold” rating to a “strong sell” rating in a research report on Saturday, January 13th. HC Wainwright raised their target price on shares of Valeant Pharmaceuticals Intl from $17.00 to $24.00 and gave the company a “buy” rating in a research report on Tuesday, January 16th. Wells Fargo & Co reissued a “sell” rating and set a $9.00 target price on shares of Valeant Pharmaceuticals Intl in a research report on Tuesday, January 16th. TD Securities raised their target price on shares of Valeant Pharmaceuticals Intl from $20.00 to $27.00 and gave the company a “buy” rating in a research report on Friday, January 5th. Finally, Cantor Fitzgerald set a $25.00 price target on shares of Valeant Pharmaceuticals Intl and gave the company a “buy” rating in a report on Friday, January 19th. Seven equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $18.09.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3231900/valeant-pharmaceuticals-intl-vrx-receiving-somewhat-positive-media-coverage-analysis-finds.html.
About Valeant Pharmaceuticals Intl
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.